Publicacións nas que colabora con Antonio Luis Valero Santiago (17)

2024

  1. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 23-32

  2. The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria

    Respiratory Medicine, Vol. 226

2023

  1. Alpha-1 antitrypsin deficiency and Pi*S and Pi*Z SERPINA1 variants are associated with asthma exacerbations

    Pulmonology

  2. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 281-288

  3. Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 223-231

  4. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti–IL-5 Biologics: A Real-Life Study

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 1, pp. 37-44

  5. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 294-296

  6. Reply to “Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies”

    Journal of Investigational Allergology and Clinical Immunology

2022

  1. Anxiety and body mass index affect asthma control: data from a prospective Spanish cohort

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 3, pp. 863-866.e1

  2. How reliably can algorithms identify eosinophilic asthma phenotypes using non-invasive biomarkers?

    Clinical and Translational Allergy, Vol. 12, Núm. 8

2021

  1. Clinical and inflammatory characteristics of patients with asthma in the Spanish MEGA project cohort

    Clinical and Translational Allergy, Vol. 11, Núm. 1

  2. Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 1, pp. 487-489.e1

  3. Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)

    Drugs

  4. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study

    Drugs, Vol. 81, Núm. 15, pp. 1763-1774

2019

  1. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 7, pp. 2277-2283.e2

2018

  1. The MEGA Project: A Study of the Mechanisms Involved in the Genesis and Disease Course of Asthma. Asthma Cohort Creation and Long-Term Follow-Up

    Archivos de Bronconeumologia, Vol. 54, Núm. 7, pp. 378-385

2017

  1. Quality indicators of asthma care derived from the spanish guidelines for asthma management (GEMA 4.0): A multidisciplinary team report

    Journal of Investigational Allergology and Clinical Immunology